Abstract Background Cardio-oncology (CO) is a multidisciplinary field focusing on the management and prevention of cardiovascular (CV) complications in cancer patients (CP) and survivors. New technologies and medicines have been developed and purposed better outcomes to CP with increased survival. Purpose: Identify cardiac risk factors (RF) and a profile of a CP through a partnership between two specialized institutes- a Cancer Institute (CI) and a Cardiology Institute (CI) involved in the management of patients with cancer and CV disease. This model promotes specialized consultations in CO and allows a quick solution to issues such as angina, Heart Failure (HF), implantation of cardiac devices and complex surgeries with the need for joint action of the cardiology and oncology teams, allowing continuity of the oncologic treatment (OT) or its cardiac complications. Methods Analysis of data from 145 consecutive patients referred for CO consultation between the OI and CI from 2019 to 2024. Data were collected retrospectively and analyzed with the R statistical package. Results The most frequent comorbidities were systemic arterial hypertension (87%), dyslipidemia (55%), diabetes (43%), tobacco use (37%) and obesity (27%). The main neoplasms involved were breast cancer (BC) (25%), lymphoma (LYM) (13%), prostate cancer (PC) (11%) and colorectal tumors (8%). The main reasons for referral were angina or evidence of myocardial ischemia (45%), dyspnea or heart failure (HF) (24%) and others (31%). The main etiology of HF was ischemic heart disease (IHD) (40%) followed by cardiotoxicity (CDTX) related to chemotherapy (10%). Although there was no statistical significance between the type of neoplasia and the etiology of HF(p=0.33), when evaluating only patients with LYM, a statistically significant association was found between LYM and CDTX (p=0.000077) and there was also a statistically significant association between CDTX and the use of anthracyclines(p=0,02). There is a statistically significant association between neoplasms in general and IHD (p=0.033), but we did not find any specific neoplasm with a significant correlation with IHD. On the other hand, in our sample, there was no statistically significant association between prior use of anthracyclines and the presence of CDTX in patients with BC.The most frequently observed neoplasms in our sample (BC, LYM, PC and colorectal cancer) are similar to those reported in other cohorts. All these findings corroborate to a new CO concept that toxicity is not only related to drug effects, but to cardiac conditions and RF that exist before, during and after treatment. Conclusions The multidisciplinary collaboration in CO is essential, enabling patients to continue their OT despite CV disease. Although our sample consists of oncology patients, IHD remains the leading etiology of HF, reinforcing that CO is not only managing chemotherapy-related side effects, but also addressing cardiovascular comorbidities
Marinho et al. (Fri,) studied this question.